5
Jan
2018

Spark Sets $850K Bar, Microsoft’s Bet on AI for Immune Mapping, & Startup Financings Galore

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Lilly Buys Centessa, Takeda & Alumis Tyk2 Showdown, & Blackstone’s Megafund
Merck Snaps Up New Cancer Drug, Denali Grows Up, & Gilead’s TCE Wager
Servier Buys Day One, Vertex Hits IgAN Phase III, & Prasad’s Unceremonious Exit at FDA
Candid Goes Public, Uniqure’s FDA Dispute, & Moderna’s Big Legal Bill